Search results for " platform" in Articles / App Notes
Article
Development of Purification for Challenging Fc-Fusion Proteins
Monoclonal antibody purification processes exist in different well-established platforms with extensive process performance histories for production of commercial mAbs (6-10), which typically consist …
Article
Unifying Continuous Biomanufacturing Operations
The two proposed platforms in that patent, however, used surge tanks, and in some embodiments of the invention, the use of a convective adsorption/desorption system was only semi-continuous (13). Whil…
Article
Optimizing Cation-Exchange Chromatography with High-Throughput Process Development for mAb Purification
An advantage in the area of mAbs is the possibility of using a purification platform approach. The typical platform process is generally comprised of an initial capture step with Protein A-chromatogra…
Article
Host-Cell Protein Measurement and Control
In late phase (Phase III or commercial), cell line-specific platform assay or upstream process-specific ELISA assay is often required to mitigate the risk associated with a more generic commercial ass…
Article
Continuous Manufacturing: A Changing Processing Paradigm
The platform flows a liquid culture medium from a perfusion bioreactor into a preliminary multi-column chromatography system (MCCS1), then the eluate of the MCCS1 containing the recombinant therapeuti…
Article
Challenges in Analytical Method Development and Validation
While the biopharmaceutical industry has had success in reducing risk by incorporating analytical platform technologies for monoclonal antibody products, new molecules and drug conjugates pose additio…
Article
Top challenges in recombinant protein purification process development
But then there's also a good platform approach that can be used. So after your affinity step, you can use a combination of ion exchangers and the monoclonal antibodies will react quite similarly each …
Article
The Importance of Process Intensification and PAT for Achieving Real-Time Release
Given the reliability of platforms and the maturity of the industry’s understanding of quality, the most important business driver today is speed to market. One consequence of this emphasis on speed i…
Article
Virus-like Particles as Therapeutic Moieties of the Future
Attempts have been taken to widen the spectrum coverage of VLP-based vaccine using chimeric systems, such as by adding a new epitope on existing VLP platforms (24).
Development of a VLP-based v…
Article
Akron Bio Will Install a Cytiva FlexFactory to Manufacture Plasmid DNA
Cytiva will provide its FlexFactory, a flexible, single-use platform, to enable Akron Biotech to manufacture plasmid DNA (pDNA), which is used in many innovative therapies and vaccines, Cytiva said in…